Summit Therapeutics (SMMT) Equity Average (2019 - 2026)

Summit Therapeutics has reported Equity Average for 8 years, with the latest figure at $602.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 64.35% year-over-year to $602.4 million; the trailing twelve-month figure through Mar 2026 stood at $602.4 million (up 64.35% YoY), and the FY2025 full-year result was $523.8 million, up 124.6% from the prior year.
• Equity Average for Q1 2026 stood at $602.4 million, up from $425.6 million in the prior quarter.
• The five-year high for Equity Average was $602.4 million in Q1 2026, with the low at $57.9 million in Q2 2022.
• Historically, Equity Average has averaged $214.2 million across 5 years, with a median of $130.0 million in 2022.
• Annual changes were most pronounced in 2024 — Equity Average plunged 53.14% — and 2025, when it surged 501.37%.
• Summit Therapeutics' Equity Average stood at $130.0 million in 2022, then sank by 31.87% to $88.5 million in 2023, then jumped by 366.86% to $413.3 million in 2024, then grew by 2.96% to $425.6 million in 2025, then jumped by 41.55% to $602.4 million in 2026.
• The last three Equity Average figures came in at $602.4 million (Q1 2026), $425.6 million (Q4 2025), and $225.9 million (Q3 2025), per Business Quant data.